Clinical Trials Directory

Trials / Conditions / Clear-cell Metastatic Renal Cell Carcinoma

Clear-cell Metastatic Renal Cell Carcinoma

21 registered clinical trials studyying Clear-cell Metastatic Renal Cell Carcinoma — 3 currently recruiting.

StatusTrialSponsorPhase
RecruitingSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Ot
NCT07227415
PfizerPhase 1 / Phase 2
Not Yet RecruitingUpfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcino
NCT06279403
RenJi HospitalPhase 2
CompletedA Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Receive
NCT05745142
Pfizer—
UnknownPembrolizumab Plus Radiotherapy for Advanced Renal Cancer
NCT05567588
Nanfang Hospital, Southern Medical UniversityPhase 2
RecruitingTrial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tum
NCT05263050
Fox Chase Cancer CenterPhase 2
CompletedCombining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
NCT02978404
Centre hospitalier de l'Université de Montréal (CHUM)Phase 2
CompletedA BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer
NCT02960906
Association Pour La Recherche des Thérapeutiques Innovantes en CancérologiePhase 2
UnknownDose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases
NCT02880943
Association Pour La Recherche des Thérapeutiques Innovantes en CancérologiePhase 1 / Phase 2
CompletedTailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
NCT02917772
AIO-Studien-gGmbHPhase 2
CompletedMLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic
NCT02724020
Millennium Pharmaceuticals, Inc.Phase 2
TerminatedTargeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers
NCT02535351
Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoPhase 3
TerminatedA Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
NCT02543645
Celldex TherapeuticsPhase 1
TerminatedA Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma
NCT02386111
Celldex TherapeuticsPhase 1
CompletedIMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC)
NCT02228954
Radboud University Medical Center—
CompletedStereotactic Radiotherapy for Metastatic Kidney Cancer Being Treated With Sunitinib
NCT02019576
Sunnybrook Health Sciences CentrePhase 2
TerminatedEvaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therap
NCT02570789
Cliniques universitaires Saint-Luc- Université Catholique de LouvainPhase 4
CompletedA Phase II Study of Axitinib in Patients With Metastatic Renal Cell Cancer Unsuitable for Nephrectomy
NCT01693822
Institute of Cancer Research, United KingdomPhase 2
CompletedBiomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Ev
NCT01715935
Association Pour La Recherche des Thérapeutiques Innovantes en CancérologiePhase 2
CompletedStudy of Efficacy and Safety of Sunitinib Given on an Individualized Schedule
NCT01499121
Sunnybrook Health Sciences CentrePhase 2
CompletedNivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Meta
NCT01472081
Bristol-Myers SquibbPhase 1
CompletedFirst Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
NCT01521715
iOMEDICO AGPhase 4